Third AACR International Meeting Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application In cooperation with the International Conference on Malignant Lymphoma (ICML) In association with *Blood Cancer Discovery*

June 23-26, 2022 | Westin Copley Place | Boston, MA

Chairs:

Riccardo Dalla-Favera, Columbia University, New York, NY Sonali M. Smith, University of Chicago, Chicago, IL


Cochairs:

Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland* Alexey V. Danilov, City of Hope National Medical Center, Duarte, CA Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, NY Teresa Palomero, Columbia University, New York, NY Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA Christian Steidl, BC Cancer, Vancouver, BC, Canada Karin Tarte, University of Rennes, Rennes, France

* - ICML Representative

[R] – REMOTE PRESENTATION

DO NOT INCLUDE IN ON-DEMAND PROGRAM



3rd International Meeting Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application

June 23-26 Westin Copley Place Boston, MA



In Cooperation with

Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application June 23-26, 2022 | Westin Copley Place | Boston, MA

Third AACR International Meeting Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application In cooperation with the International Conference on Malignant Lymphoma (ICML) In association with *Blood Cancer Discovery*

June 23-26, 2022 | Westin Copley Place | Boston, MA

THURSDAY, JUNE 23

Registration

12:00 pm-7:00 pm | America Ballroom Foyer

Welcome and Opening Keynote Session

3:00 pm-5:00 pm | America Ballroom North and Center

3:00-3:10	Welcome and Introduction of Keynote Speaker Riccardo Dalla-Favera, Columbia University, New York, NY
3:10-3:40	Therapeutic vulnerabilities uncovered by B-cell/stromal crosstalk Karin Tarte, University of Rennes, Rennes, France
3:40-3:50	Q&A / Discussion
3:50-3:55	Introduction of Keynote Speaker Riccardo Dalla-Favera, Columbia University, New York, NY
3:55-4:25	[R] - Integrating bispecific antibodies into lymphoma therapy Adrian U. Wiestner, National Heart, Lung, and Blood Institute, Bethesda, MD
4:25-4:35	Q&A / Discussion
4:35-5:00	Panel Discussion

Break

5:00 pm-5:30 pm | America Ballroom Foyer

Advances in Malignant Lymphoma:

Maximizing the Basic-Translational Interface for Clinical Application

In cooperation with the International Conference on Malignant Lymphoma (ICML)

In association with *Blood Cancer Discovery*

June 23-26, 2022 | Westin Copley Place | Boston, MA

Plenary Session 1: CAR-T

5:30 pm-7:00 pm | America Ballroom North and Center Session Chair: Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, TX

5:30-5:50	Lessons from CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, TX
5:50-5:55	Q&A / Discussion
5:55-6:15	Anti-CD19 Chimeric Antigen Receptor T-cells in CLL: A decade in review Jan Joseph Melenhorst, Cleveland Clinic Lerner Research Institute, Cleveland, OH
6:15-6:20	Q&A / Discussion
6:20-6:40	Challenge accepted: CAR-T cells for T-cell malignancies Rayne H. Rouce, Baylor College of Medicine, Houston, TX
6:40-6:45	Q&A / Discussion
6:45-7:00	Panel Discussion

Opening Reception

7:00 pm-9:00 pm | America Ballroom South

FRIDAY, JUNE 24

Breakfast 7:00 am-8:00 am | America Ballroom South

Special Session 1: Initial Treatment of DLBCL: Are We in a New Era?

7:30 am-8:30 am | America Ballroom North and Center Session Chair: Laurie H. Sehn, BC Cancer, Vancouver, BC, Canada

7:30-7:45	Molecular classification of DLBCL: Utlilty and barriers to implementation Grzegorz S. Nowakowski, Mayo Clinic College of Medicine and Science, Rochester, MN
7:45-7:50	Q&A / Discussion
7:50-8:05	Is there a new one-size-fits-all standard of care in DLBCL? Laurie H. Sehn, BC Cancer, Vancouver, BC, Canada
8:05-8:10	Q&A / Discussion
8:10-8:30	Panel Discussion

Advances in Malignant Lymphoma:

Maximizing the Basic-Translational Interface for Clinical Application

In cooperation with the International Conference on Malignant Lymphoma (ICML)

In association with Blood Cancer Discovery

June 23-26, 2022 | Westin Copley Place | Boston, MA

Break

8:30 am-8:45 am | America Ballroom Foyer

Plenary Session 2: Evolution of Liquid Biopsies for Lymphoma

8:45 am-10:15 am | America Ballroom North and Center

Session Chair: Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland

8:45-9:05 9:05-9:10	Understanding the biology of classic Hodgkin lymphoma using circulating tumor DNA Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland Q&A / Discussion
9:10-9:30 9:30-9:35	Circulating tumor DNA profiling for noninvasive disease detection and MRD monitoring in patients with CNS lymphoma Florian Scherer, University Medical Center Freiburg, Freiburg, Germany Q&A / Discussion
9:35-9:55 9:55-10:00	[R] – Next generation methods for disease detection and characterization from circulating tumor DNA David M. Kurtz, Stanford University Medical Center, Stanford, CA Q&A / Discussion

10:00-10:15 Panel Discussion

Break

10:15 am-10:30 am | America Ballroom Foyer

Advances in Malignant Lymphoma:

Maximizing the Basic-Translational Interface for Clinical Application

In cooperation with the International Conference on Malignant Lymphoma (ICML)

In association with Blood Cancer Discovery

June 23-26, 2022 | Westin Copley Place | Boston, MA

Plenary Session 3: Germinal Center Biology

10:30 am-12:00 pm | America Ballroom North and Center Session Chair: Riccardo Dalla-Favera, Columbia University, New York, NY

10:30-10:50	[R] – T cell help and B cell selection in germinal centers Gabriel D. Victora, The Rockefeller University, New York, NY
10:50-10:55	Q&A / Discussion
10:55-11:15	Human germinal center responses to vaccination Michela Locci, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
11:15-11:20	Q&A / Discussion
11:20-11:40	[R] - Lymphoma mutations in the evolution of pathogenic autoantibodies Joanne Reed, The Westmead Institute for Medical Research, Westmead, NSW, Australia
11:40-11:45	Q&A / Discussion

11:45-12:00 Panel Discussion

Lunch Available

12:00 pm-1:30 pm | America Ballroom South

Plenary Session 4: Epigenetics

1:30 pm-3:00 pm | America Ballroom North and Center Session Chair: Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, NY

1:30-1:50 1:50-1:55	BAF complex deregulation in lymphoma Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX Q&A / Discussion
1:55-2:15	Novel interactions between epigenetic regulators altered in B cell lymphoma Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, NY
2:15-2:20	Q&A / Discussion
2:20-2:40	How to leverage epigenetic therapeutic interventions in FL? Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, NY
2:40-2:45	Q&A / Discussion
2:45-3:00	Panel Discussion

Advances in Malignant Lymphoma:

Maximizing the Basic-Translational Interface for Clinical Application

In cooperation with the International Conference on Malignant Lymphoma (ICML)

In association with Blood Cancer Discovery

June 23-26, 2022 | Westin Copley Place | Boston, MA

Break

3:00 pm-3:15 pm | America Ballroom Foyer

Plenary Session 5: Modeling for Pre-clinical

3:15 pm-4:45 pm | America Ballroom North and Center Session Chair: Giorgio Inghirami, Weill Cornell Medicine, New York, NY

3:15-3:35	Pre-clinical investigation using patient-derived xenograft modeling of aggressive and indolent B-cell lymphomas
	Abner Louissaint, Massachusetts General Hospital, Boston, MA
3:35-3:40	Q&A / Discussion
3:40-4:00	Modeling EZH2 mutant follicular lymphomas Wendy Béguelin, Weill Cornell Medicine, New York, NY
4:00-4:05	Q&A / Discussion
4:05-4:25	Translational research on mantle cell lymphoma: From lab to clinic Michael Wang, The University of Texas MD Anderson Cancer Center, Houston, TX
4:25-4:30	Q&A / Discussion
4:30-4:45	Panel Discussion

Poster Session / Reception

5:00 pm-7:00 pm | America Ballroom South

Advances in Malignant Lymphoma:

Maximizing the Basic-Translational Interface for Clinical Application

In cooperation with the International Conference on Malignant Lymphoma (ICML)

In association with Blood Cancer Discovery

June 23-26, 2022 | Westin Copley Place | Boston, MA

SATURDAY, JUNE 25

Breakfast

7:00 am-8:00 am | America Ballroom South

Special Session 2: Mantle Cell Lymphoma

7:30 am-8:30 am | America Ballroom North and Center Session Chair: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland

7:30-7:45	Dynamic changes in gene mutational landscape with preservation of core mutations in mantle cell lymphoma Mariusz A. Wasik, Fox Chase Cancer Center, Philadelphia, PA
7:45-7:50	Q&A / Discussion
7:50-8:05	[R] - Targeting SOX11 in mantle cell lymphoma Samir Parekh, Icahn School of Medicine at Mount Sinai, New York, NY
8:05-8:10	Q&A / Discussion

8:10-8:30 Panel Discussion

Break

8:30 am-8:45 am | America Ballroom Foyer

Plenary Session 6: DLBCL: Genomics Toward Precision Therapy

8:45 am-10:15 am | America Ballroom North and Center

Session Chair: Riccardo Dalla-Favera, Columbia University, New York, NY

8:45-9:05	Leveraging functional and structural genomics for precision medicine James D. Phelan, National Cancer Institute, Bethesda, MD
9:05-9:10	Q&A / Discussion
9:10-9:30	Understanding lymphoma biology and improving classification through comprehensive sequencing
	Ryan D. Morin, Simon Fraser University, Vancouver, BC, Canada
9:30-9:35	Q&A / Discussion
9:35-9:55	Pervasive hypermutation of super-enhancers dysregulates oncogene expression in DLBCL
	Riccardo Dalla-Favera, Columbia University, New York, NY
9:55-10:00	Q&A / Discussion
10:00-10:15	Panel Discussion

Advances in Malignant Lymphoma:

Maximizing the Basic-Translational Interface for Clinical Application

In cooperation with the International Conference on Malignant Lymphoma (ICML)

In association with Blood Cancer Discovery

June 23-26, 2022 | Westin Copley Place | Boston, MA

Break

10:15 am-10:30 am | America Ballroom Foyer

Plenary Session 7: FL and CLL Evolution and Transformation

10:30 am-12:00 pm | America Ballroom North and Center Session Chair: Catherine J. Wu, Dana Farber Cancer Institute, Boston, MA

10:30-10:50 10:50-10:55	Human genetic studies: CLL and transformation Catherine J. Wu, Dana Farber Cancer Institute, Boston, MA Q&A / Discussion
10:55-11:15	Understanding CLL and Richter's syndrome biology through mouse models of human genetics Elisa ten Hacken, Dana Farber Cancer Institute, Boston, MA
11:15-11:20	Q&A / Discussion
11:20-11:40	[R] - Follicular lymphoma and transformation Jessica Okosun, Queen Mary University of London, London, England
11:40-11:45	Q&A / Discussion

11:45-12:00 Panel Discussion

Lunch Available

12:00 pm-1:30 pm | America Ballroom South

Special Session 3: T-cell Lymphomas

12:30 pm-1:30 pm | America Ballroom North and Center Session Chair: Teresa Palomero, Columbia University, New York, NY

12:30-12:45	Genomic alterations and mouse models in PTCL Teresa Palomero, Columbia University, New York, NY
12:45-12:50	Q&A / Discussion
12:50-1:05	The role of PD1 in t cell lymphomas Jaehyuk Choi , Northwestern University, Chicago, IL
1:05-1:10	Q&A / Discussion
1:10-1:30	Panel Discussion

Advances in Malignant Lymphoma:

Maximizing the Basic-Translational Interface for Clinical Application

In cooperation with the International Conference on Malignant Lymphoma (ICML)

In association with Blood Cancer Discovery

June 23-26, 2022 | Westin Copley Place | Boston, MA

Plenary Session 8: New Technologies

1:45 pm-3:15 pm | America Ballroom North and Center Session Chair: Kojo S.J. Elenitoba-Johnson, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

1:45-2:05	Lost in ubiquitination, found by mass spectrometry: Novel proteolytic mechanisms implicated in lymphoma transformation Kojo S.J. Elenitoba-Johnson, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
2:05-2:10	Q&A / Discussion
2:10-2:30	A multi-scale, multiomic atlas of human normal and follicular lymphoma lymph nodes Andrea Radtke, National Institute of Allergy and Infectious Diseases, Bethesda, MD
2:30-2:35	Q&A / Discussion
2:35-2:55	[R] -Elucidation of lymphoma biology by proteogenomics Thomas Oellerich, Goethe University Hospital, Frankfurt, Germany
2:55-3:00	Q&A / Discussion
3:00-3:15	Panel Discussion

Break

3:15 pm-3:30 pm | America Ballroom Foyer

Plenary Session 9: Immune Evasion in Hodgkin and Non-Hodgkin Lymphomas

3:30 pm-5:00 pm | America Ballroom North and Center Session Chair: Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA

3:30-3:50 3:50-3:55	Genetic bases of immune evasion in lymphoid malignancies Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA Q&A / Discussion
3:55-4:15	New imaging approaches to characterize the intact tumor microenvironment Scott J. Rodig, Brigham and Women's Hospital, Boston, MA
4:15-4:20	Q&A / Discussion
4:20-4:40	The DLBCL immune landscape: Evidence for immune surveillance, evasion, and exclusion Justin P. Kline, University of Chicago, Chicago, IL
4:40-4:45	Q&A / Discussion

Third AACR International Meeting Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application In cooperation with the International Conference on Malignant Lymphoma (ICML) In association with Blood Cancer Discovery

June 23-26, 2022 | Westin Copley Place | Boston, MA

4:45-5:00 Panel Discussion Break 5:00 pm-5:30 pm | America Ballroom Foyer

Special Session 4: Industry Roundtable

5:30 pm-6:30 pm | America Ballroom North and Center Session Chair: Anas Younes, AstraZeneca, New York, NY

5:30-5:40	[R] - Adam S. Crystal, C4 Therapeutics, Watertown, MA
5:40-5:45	Q&A / Discussion
5:45-5:55	Gwenn Hansen, Nurix Therapeutics, Inc., San Francisco, CA
5:55-6:00	Q&A / Discussion
6:00-6:10	Clinical experience with off-the-shelf iPSC derived cell therapies in hematologic
	malignancies
	Yu-Waye (Wayne) Chu, Fate Therapeutics, San Diego, CA
6:10-6:15	Q&A / Discussion
6:15-6:30	Panel Discussion

SUNDAY, JUNE 26

Breakfast

7:00 am-8:00 am | America Ballroom South

Special Session 5: AYA Lymphomas

7:30 am-8:30 am | America Ballroom North and Center Session Chair: Andrew M. Evens, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

7:30-7:45	Pathology of AYA lymphomas: Creating a roadmap for translational discovery Megan S. Lim, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
7:45-7:50	Q&A / Discussion
7:50-8:05	Unmet clinical research questions in AYA lymphomas Jamie E. Flerlage, St. Jude Children's Research Hospital, Memphis, TN
8:05-8:10	Q&A / Discussion
8:10-8:30	Panel Discussion

Advances in Malignant Lymphoma:

Maximizing the Basic-Translational Interface for Clinical Application

In cooperation with the International Conference on Malignant Lymphoma (ICML)

In association with Blood Cancer Discovery

June 23-26, 2022 | Westin Copley Place | Boston, MA

Break

8:30 am-8:45 am | America Ballroom Foyer

Plenary Session 10: Metabolism and Immunometabolism in Lymphoid Malignancies: A New Target? 8:45 am-10:15 am | America Ballroom North and Center Session Chair: Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, NY

8:45-9:05 9:05-9:10	Metabolic communication between the lymphoma microenvironments Leandro C. Cerchietti, Weill Cornell Medicine, New York, NY Q&A / Discussion
9:10-9:30	Title to be announced
	Nika N. Danial, Dana-Farber Cancer Institute, Boston, MA
9:30-9:35	Q&A / Discussion
9:35-9:55	Multi-omic analysis reveals B-cell stimulus-specific oncogenic pathway responses and targets
	Benjamin E. Gewurz, Brigham and Women's Hospital, Boston, MA
9:55-10:00	Q&A / Discussion
10:00-10:15	Panel Discussion

Break

10:15 am-10:30 am | America Ballroom Foyer

Plenary Session 11: Moving Beyond the Basics in PET: Functional Imaging in Lymphoma

10:30 am-12:00 pm | America Ballroom North and Center Session Chair: Judith Trotman, University of Sydney, Sydney, Australia

10:30-10:50	Recent and future developments in PET imaging of lymphoma Heiko Schőder, Memorial Sloan Kettering Cancer Center, New York, NY
10:50-10:55	Q&A / Discussion
10:55-11:15	FDG-PET in FL: Staging, response assessment, and beyond Stefano Luminari, University of Modena and Reggio Emilia, Modena, Italy
11:15-11:20	Q&A / Discussion
11:20-11:40	PET in diffuse large B cell lymphoma Judith Trotman, University of Sydney, Sydney, Australia
11:40-11:45	Q&A / Discussion
11:45-12:00	Panel Discussion

Advances in Malignant Lymphoma:

Maximizing the Basic-Translational Interface for Clinical Application

In cooperation with the International Conference on Malignant Lymphoma (ICML)

In association with Blood Cancer Discovery

June 23-26, 2022 | Westin Copley Place | Boston, MA

Break

12:00 pm-12:15 pm | America Ballroom Foyer

Plenary Session 12: Exploiting NK Cell-therapy in Lymphomas

12:15 pm-1:45 pm | America Ballroom North and Center Session Chair: Riccardo Dalla-Favera, Columbia University, New York, NY

12:15-12:35	Development of nicotinamide enhanced NK cell therapeutics for lymphoma Veronika S. Bachanova, University of Minnesota, Minneapolis, MN
12:35-12:40	Q&A / Discussion
12:40-1:00	Driving innate recognition and engineering memory-like NK cells in lymphoma Melissa M. Berrien-Elliott, Washington University School of Medicine, St. Louis, MO
1:00-1:05	Q&A / Discussion
1:05-1:25	IL-21 expanded, off the shelf, third-party NK cells: Novel therapies for lymphoma John C. Reneau, The Ohio State University Wexner Medical Center, Columbus, OH
1:25-1:30	Q&A / Discussion
1:30-1:45	Panel Discussion

Closing Comments and Departure

1:45 pm | America Ballroom North and Center

Riccardo Dalla-Favera, Columbia University, New York, NY